Explore the words cloud of the MICROB-PREDICT project. It provides you a very rough idea of what is the project "MICROB-PREDICT" about.
The following table provides information about the project.
Coordinator |
EUROPEAN FOUNDATION FOR THE STUDY OF CHRONIC LIVER FAILURE (EF-CLIF)
Organization address contact info |
Coordinator Country | Spain [ES] |
Total cost | 15˙000˙002 € |
EC max contribution | 15˙000˙000 € (100%) |
Programme |
1. H2020-EU.3.1.2. (Preventing disease) |
Code Call | H2020-SC1-2018-Single-Stage-RTD |
Funding Scheme | RIA |
Starting year | 2019 |
Duration (year-month-day) | from 2019-01-01 to 2025-03-31 |
Take a look of project's partnership.
Decompensation of liver cirrhosis and progression towards acute-on-chronic liver failure (ACLF) causes 1.2 million deaths/year. Microbiome is causally involved in cirrhosis progression and is for drugs the first interaction point with the patients. Drugs can alter the microbiome leading to unwanted effects or even facilitating their effects, but the microbiome metabolizes the drugs, shapes their effects and possibly determines the host response to drugs. As each person carries an individual microbiome, insight in these processes should help stratify or even personalize patient health care and treatment. The aims of MICROB-PREDICT are 1) to better understand the role of microbiome and the gut-liver-axis interactome with respect to microbiome functionalities, 2) to identify and validate microbiome-based biomarkers and signatures for personalized prediction of decompensation and ACLF, and response to treatment, 3) to design three new tests as easy-to-use tools and point-of-care, smartphone-connected nanobiosensors, and 4) to validate them in a randomized controlled trial. MICROB-PREDICT will assemble existing data and samples from major microbiome initiatives in hepatology (12 international studies, >10,000 patients), and enrich them with holistic and in-depth analysis using cutting-edge multi-omics technologies of host and microbiome from different body sites in samples of >1,000 patients collected in a longitudinal manner with sequential visits and controlling for confounders. MICROB-PREDICT results will foster more accurate, personalized risk stratification and significant steps towards personalized treatment of decompensated cirrhosis and ACLF. World-leading microbiome specialists, technology leaders and clinical experts make this a programme of scientific excellence; patient organisations (ELPA) and the European Association for the study of the Liver (EASL) will channel our results into a powerful dissemination, communication and exploitation programme.
Project brochure and professional templates | Websites, patent fillings, videos etc. | 2020-04-25 11:37:03 |
Go-online of the public project website | Websites, patent fillings, videos etc. | 2020-04-25 11:37:03 |
Take a look to the deliverables list in detail: detailed list of MICROB-PREDICT deliverables.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MICROB-PREDICT" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "MICROB-PREDICT" are provided by the European Opendata Portal: CORDIS opendata.